Can a diabetes drug stop prediabetes in its tracks?

NCT ID NCT07392151

Not yet recruiting Disease control Sponsor: Michael Mæng Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether glucose-lowering medications (semaglutide and possibly dapagliflozin) can reverse prediabetes and prevent complications like eye, kidney, and nerve damage in people with heart disease. About 158 participants with prediabetes and coronary artery disease will be randomly assigned to either intensive treatment or standard care, and followed for two years. A third group of 50 people with normal blood sugar will serve as a comparison.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Semaglutide and possibly Dapagliflozin
What this could lead to: If successful, this could show that treating prediabetes with these drugs can restore normal blood sugar and reduce the risk of diabetes-related complications.
What could go wrong: This is a relatively small trial (158 participants) and the drugs are not yet approved for prediabetes. Results may not apply to everyone, and side effects from the medications are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC CORONARY SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder kidney disorder prediabetes syndrome retinal disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC CORONARY SYNDROME PREDIABETES

Contacts and locations

Locations

Aarhus University Hospital

Aarhus N, 8200, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.